Cabazitaxel suppresses colorectal cancer cell growth via enhancing the p53 antitumor pathway
There were approximately 1.93 million new cases and 940 000 deaths from colorectal cancer in 2020. The first‐line chemotherapeutic drugs for colorectal cancer are mainly based on 5‐fluorouracil, although the use of these drugs is limited by the development of drug resistance. Consequently, there is...
Saved in:
| Main Authors: | Wen Zhang, Ruiqian Sun, Yongjun Zhang, Rong Hu, Qian Li, Weili Wu, Xinyu Cao, Jiajian Zhou, Jianfeng Pei, Ping Yuan |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-11-01
|
| Series: | FEBS Open Bio |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/2211-5463.13290 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Knockout of the sulfide: quinone oxidoreductase SQR reduces growth of HCT116 tumor xenograft
by: Ting Lu, et al.
Published: (2025-06-01) -
Design, synthesis and antitumor activity of 3,4,5-Trisubstituted Isoxazoles
by: Kanghui Duan, et al.
Published: (2024-12-01) -
ESTIMATION OF TOXIC EFFECTS OF MEDICINAL PREPARATION OF CABAZITAXEL
by: O. I. Avdeeva, et al.
Published: (2019-01-01) -
Inhibition of Mitochondrial Dynamics by Mitochondrial Division Inhibitor-1 Suppresses Cell Migration and Metastatic Markers in Colorectal Cancer HCT116 Cells
by: Mehmood T, et al.
Published: (2025-03-01) -
Decreasing the ability of HCT116 cells to escape from therapy induced senescence by increasing the duration of doxorubicin treatment
by: N. A. Persiyantseva, et al.
Published: (2024-04-01)